Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent losses that threaten to wipe out all the gains since the drugmaker launched ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic and Wegovy.

Shares in Novo Nordisk NOVO.B-1.81%decrease; red down pointing triangle plunged after it cut its guidance, a result from the company losing its lead in the booming market for weight-loss drugs ...

Manufacturing Regeneron says Novo plant problems caused another CRL and will delay 2 Eylea decisions By Kevin Dunleavy Aug 1, 2025 11:51am Regeneron Pharmaceuticals Eylea drug manufacturing Novo ...

Wall Street is reacting with downgrades to Novo's earnings, but with shares trading at their lowest valuation in years, patient investors could find opportunity as the stock falls.

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in ...

Novo Nordisk shares dropped after slashing full-year sales guidance, primarily due to weakening sales of its blockbuster GLP-1 drugs, Ozempic and Wegovy.

We recently published 10 Stocks That Jim Cramer Talked About. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer recently discussed. Novo Nordisk A/S (NYSE:NVO) came up during the show in ...

Can Novo Nordisk’s New CEO Stop Rivals From Taking Over the Anti-Obesity Market? Company’s first non-Danish leader, Maziar Mike Doustdar, will face a challenging landscape in the U.S.

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a profit warning and named a new CEO, as it battles rising competition in ...

Novo Nordisk slumps as it cuts sales forecast, names new CEO Novo Nordisk's new chief executive, Mike Doustdar, will replace Lars Fruergaard Jørgensen on 7th August.

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.